US BANCORP \DE\ - BIOCRYST PHARMACEUTICALS INC ownership

BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 241 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.25 and the average weighting 0.3%.

Quarter-by-quarter ownership
US BANCORP \DE\ ownership history of BIOCRYST PHARMACEUTICALS INC
ValueSharesWeighting
Q1 2023$9,391
+874.2%
1,126
+1240.5%
0.00%
Q4 2022$964
-3.6%
84
-24.3%
0.00%
Q3 2022$1,0000.0%111
+32.1%
0.00%
Q2 2022$1,000
-99.5%
84
-99.3%
0.00%
Q1 2022$197,000
+22.4%
12,100
+4.3%
0.00%
Q4 2021$161,000
+30.9%
11,600
+35.0%
0.00%
Q3 2021$123,000
-7.5%
8,594
+2.3%
0.00%
Q2 2021$133,000
+14.7%
8,400
-26.3%
0.00%
Q1 2021$116,000
+673.3%
11,400
+470.0%
0.00%
Q4 2020$15,000
+200.0%
2,000
+100.0%
0.00%
Q2 2020$5,000
-61.5%
1,000
-78.5%
0.00%
Q3 2019$13,000
-27.8%
4,6480.0%0.00%
Q2 2019$18,000
+500.0%
4,648
+1243.4%
0.00%
Q1 2019$3,0000.0%346
-9.9%
0.00%
Q1 2015$3,000
-40.0%
3840.0%0.00%
Q4 2014$5,000
+25.0%
3840.0%0.00%
Q3 2014$4,0003840.00%
Other shareholders
BIOCRYST PHARMACEUTICALS INC shareholders Q1 2023
NameSharesValueWeighting ↓
Burrage Capital Management LLC 864,916$13,674,00013.71%
Sarissa Capital Management LP 4,261,000$67,366,0005.36%
ORACLE INVESTMENT MANAGEMENT INC 1,920,733$30,367,0004.18%
HealthCor Management, L.P. 3,248,100$51,352,0002.05%
Parkman Healthcare Partners LLC 351,961$5,565,0001.22%
Bain Capital Public Equity Management II, LLC 1,560,730$24,675,0001.06%
Baker Brothers Advisors 12,710,818$200,958,0000.88%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,835,000$44,821,0000.80%
Biondo Investment Advisors, LLC 265,840$4,203,0000.72%
EAM Global Investors LLC 157,065$2,483,0000.69%
View complete list of BIOCRYST PHARMACEUTICALS INC shareholders